首页> 外文OA文献 >Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

【2h】

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

机译：患有固体瘤患者的LB-100，蛋白质磷酸酶2a抑制剂的安全性，耐受性和初步活性：开放标签，剂量升级，首先 - 人，I期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vincent Chung; Aaron S. Mansfield; Fadi Braiteh; Donald Richards; Henry Durivage; Richard S. Ungerleider; Francis Johnson; John S. Kovach;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial [J] . Chung Vincent, Mansfield Aaron S., Braiteh Fadi, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第13期

机译：患有固体瘤患者的LB-100，蛋白质磷酸酶2a抑制剂的安全性，耐受性和初步活性：开放标签，剂量升级，首先 - 人，I期试验
2. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial [J] . Younes Anas, Berdeja Jesus G., Patel Manish R., The lancet oncology . 2016,第5期

机译：HDAC和PI3K的双重口服抑制剂CUDC-907在复发或难治性淋巴瘤或多发性骨髓瘤患者中的安全性，耐受性和初步活性：开放标签，剂量递增，1期试用
3. A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-beta pathways, in patients with metastatic or locally advanced solid tumors [J] . Strauss J., Heery C., Schlom J., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：I期开放性多剂量临床试验，旨在研究M7824（一种靶向PD-L1和TGF-β途径的新型双功能融合蛋白）的安全性，耐受性，药代动力学，生物学和临床活性转移性或局部晚期实体瘤
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Safety tolerability pharmacokinetics and pharmacodynamics of the afucosylated humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors [O] . Kohei Shitara, Taroh Satoh, Satoru Iwasa, 2019

机译：无岩藻糖基化的人源化抗EPHA2抗体DS-8895a的安全性耐受性药代动力学和药效学：在患有晚期实体瘤的患者中进行的人体内第一阶段I剂量递增和剂量扩展研究
7. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial [O] . Anas Younes, Jesus G Berdeja, Manish R Patel, 2016

机译：CUDC-907的安全性，耐受性和初步活动，复发或难治性淋巴瘤或多发性骨髓瘤的患者中，HDAC和PI3K的一流，口服，双抑制剂：多种骨髓瘤：开放标签，剂量升级，阶段1审判

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

著录项

引文网络

相似文献

相关主题

期刊订阅